2022
The Impact of Access to Addiction Specialist on Attitudes, Beliefs and Hospital-Based Opioid Use Disorder Related Care: A Survey of Hospitalist Physicians
Calcaterra SL, Binswanger IA, Edelman EJ, McNair BK, Wakeman SE, O'Connor P. The Impact of Access to Addiction Specialist on Attitudes, Beliefs and Hospital-Based Opioid Use Disorder Related Care: A Survey of Hospitalist Physicians. Substance Use & Addiction Journal 2022, 43: 143-151. PMID: 32267807, PMCID: PMC7541600, DOI: 10.1080/08897077.2020.1748169.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction specialistsLocal treatment resourcesLife-saving treatmentBuprenorphine initiationMultivariable analysisOUD careScreening practicesHospitalist physiciansUse disordersClinical practicePatientsRelated careTreatment resourcesHospitalistsHarm reductionCareTreatmentUnited StatesSpecialistsOnline surveyHospitalizationBuprenorphineComplicationsPrescribing
2021
The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review
Kumar N, Oles W, Howell BA, Janmohamed K, Lee ST, Funaro MC, O'Connor PG, Alexander M. The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review. Journal Of Substance Use And Addiction Treatment 2021, 127: 108367. PMID: 34134871, PMCID: PMC9022048, DOI: 10.1016/j.jsat.2021.108367.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersTreatment outcomesMedication treatmentMOUD treatmentSystematic reviewOpioid use disorder treatmentSocial network supportPositive social support networksUse disorder treatmentPatients' oddsOpioid deathsPatient populationSuccessful treatmentOpioid epidemicInclusion criteriaResearch DatabaseElectronic research databasesHealthy behaviorsDisorder treatmentTools physiciansTargeted interventionsDisordersMedicationsTreatment
2020
Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O’Connor P, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial. Addiction Science & Clinical Practice 2020, 15: 28. PMID: 32727618, PMCID: PMC7388231, DOI: 10.1186/s13722-020-00200-y.Peer-Reviewed Original ResearchConceptsRisk alcohol useAlcohol useAlcohol treatmentHealth of patientsEvidence-based strategiesWeek 24HIV outcomesRoutine careTelephone boosterPhysician managementEnhancement therapyHIVPWHPatientsTrialsTarget populationTreatmentAlcohol-related researchMulti-pronged approachOutcomesParticipantsInsufficient numberTherapyPopulationMethodsIn
2019
Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial. Journal Of Substance Use And Addiction Treatment 2019, 106: 97-106. PMID: 31540617, PMCID: PMC7244228, DOI: 10.1016/j.jsat.2019.08.007.Peer-Reviewed Original Research
2017
Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice
Donroe JH, Holt SR, O’Connor P, Sukumar N, Tetrault JM. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug And Alcohol Dependence 2017, 180: 46-51. PMID: 28866369, DOI: 10.1016/j.drugalcdep.2017.07.040.Peer-Reviewed Original ResearchConceptsOpioid use disorderUrine buprenorphineNorbuprenorphine levelsUrine adulterationAddiction treatment clinicsTreatment clinicsBuprenorphine medicationSublingual buprenorphineBuprenorphine treatmentTreatment cohortsRetrospective studyUrine specimenBuprenorphineUse disordersPatientsClinical practiceUrine samplesUrineClinicTreatmentMedicationsLevelsNorBUPCohortSuspicion
2012
Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice
Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice. The American Journal Of Drug And Alcohol Abuse 2012, 38: 187-199. PMID: 22404717, PMCID: PMC4331107, DOI: 10.3109/00952990.2011.653426.Peer-Reviewed Original ResearchConceptsΜ-opioid receptor antagonist naltrexoneSignificant public health problemDose of buprenorphinePublic health problemLevel of careOral naltrexoneOpioid detoxificationAntagonist naltrexoneOpioid dependencePatient selectionOpioid agonistsAgonist maintenanceAncillary medicationsFavorable outcomeHigh riskTarget doseClinical practiceHealth problemsNaltrexoneExpert cliniciansTreatmentDoseMore researchUseful alternativeBest approach
2011
Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatmentMedications for unhealthy alcohol use: across the spectrum.
O'Malley SS, O'Connor PG. Medications for unhealthy alcohol use: across the spectrum. Alcohol Research 2011, 33: 300-12. PMID: 23580015, PMCID: PMC3860540.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useSpecialty careCare settingsAlcohol useAdvent of pharmacotherapyPrimary care providersPrimary care settingSpectrum of careHealth care settingsPrimary careCare providersHazardous drinkersEarly interventionExcessive drinkingCareAlcohol problemsTreatmentMedicationsPharmacotherapyPatientsCliniciansPrevalenceSettingDrinkers
2009
The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office‐Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence
Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA. The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office‐Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence. American Journal On Addictions 2009, 19: 53-58. PMID: 20132122, PMCID: PMC3107713, DOI: 10.1111/j.1521-0391.2009.00003.x.Peer-Reviewed Original ResearchConceptsOpioid-negative urinesBuprenorphine/naloxoneUrine toxicology testsWeeks of treatmentWorse treatment outcomesTreatment outcomesCocaine useTreatment retentionMean weekBuprenorphine/naloxone maintenanceGreater percentageToxicology testsUrine toxicology resultsOpioid dependenceToxicology resultsPatientsTargeted interventionsWeeksNaloxoneOutcomesTreatmentBaselineUrineAssociationPercentage
2008
Substance Abuse and Withdrawal in the Critical Care Setting
Tetrault JM, O'Connor PG. Substance Abuse and Withdrawal in the Critical Care Setting. Critical Care Clinics 2008, 24: 767-788. PMID: 18929942, DOI: 10.1016/j.ccc.2008.05.005.Commentaries, Editorials and LettersConceptsCritical care settingWithdrawal syndromeCare settingsOverall treatment protocolSubstance useSubstance withdrawal syndromeSymptom-triggered approachCritical care teamTapering doseAcute presentationResuscitative measuresCare teamTreatment protocolHigh indexSubstance intoxicationSubstance abuseAbused drugsSyndromeTreatmentWithdrawalEpidemiologySettingSuspicionDoseIntoxicationCost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients
Jones ES, Moore BA, Sindelar JL, O’Connor P, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug And Alcohol Dependence 2008, 99: 132-140. PMID: 18804923, PMCID: PMC2646001, DOI: 10.1016/j.drugalcdep.2008.07.013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBuprenorphineCohort StudiesCost of IllnessCosts and Cost AnalysisData Interpretation, StatisticalFemaleHealth PersonnelHumansMaleMethadoneMiddle AgedNarcoticsOpioid-Related DisordersPhysicians' OfficesSocioeconomic FactorsSubstance Abuse DetectionSubstance Abuse Treatment CentersTreatment OutcomeYoung AdultConceptsOffice-based treatmentOpioid dependencePatient costsClinical contactMonthly medication costsOffice-based buprenorphineOffice-based methadoneMonths of treatmentAnalysis of treatmentTotal monthly costsChi-square testMonths of maintenanceStable patientsMedication costsPatientsMethadoneMonthly costBuprenorphineTreatmentMonthsStatistical comparisonCost estimatesClinicLong‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years
Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years. American Journal On Addictions 2008, 17: 116-120. PMID: 18393054, DOI: 10.1080/10550490701860971.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCombined Modality TherapyCounselingCross-Sectional StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHeroin DependenceHumansLong-Term CareMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPatient DropoutsPrimary Health CareSubstance Abuse DetectionTreatment OutcomeConceptsOpioid-dependent patientsAdverse eventsSerum transaminasesBuprenorphine/naloxone treatmentSerious adverse eventsBuprenorphine/naloxoneLong-term outcomesOffice-based treatmentIllicit drug useOpioid useClinical stabilityNaloxone treatmentPrimary outcomePatient satisfactionPrimary careTerm treatmentDrug useUrine samplesPatientsTreatmentTransaminaseOutcomesYearsModerate levelsPercent
2007
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors
Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, Schottenfeld RS, Fiellin DA. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal Of Substance Use And Addiction Treatment 2007, 35: 87-92. PMID: 17933486, PMCID: PMC2587397, DOI: 10.1016/j.jsat.2007.08.004.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentNaloxone treatmentHIV risk behaviorsHIV riskRisk behaviorsHuman immunodeficiency virus (HIV) risk behaviorsDrug-related HIV riskHuman immunodeficiency virus (HIV) riskSex-related HIV risk behaviorsBuprenorphine/naloxoneIntravenous drug useOpioid-dependent personsPrimary care clinicsInconsistent condom useBuprenorphine/Care clinicsMethadone treatmentPrimary careDrug useSteady partnerCondom useBaselineWeeksTreatmentPatientsPatient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment
Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O’Connor P, Schottenfeld RS, Fiellin DA. Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment. Journal Of General Internal Medicine 2007, 22: 242-245. PMID: 17356993, PMCID: PMC1824745, DOI: 10.1007/s11606-006-0050-y.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxonePatient satisfactionBuprenorphine/naloxone treatmentDrug treatment historyOpioid-dependent patientsPrimary care officesOpioid-dependent subjectsSubstance use statusOverall satisfaction scoreOffice visit frequencyNaloxone treatmentParticipantsOne hundredPrimary outcomeCare officesFemale genderTreatment historyPatientsNaloxoneSatisfaction scoresEthnicity/raceTreatment locationUse statusVisit frequencyMedicationsTreatment
2004
Processes of Care During a Randomized Trial of Office‐based Treatment of Opioid Dependence in Primary Care
Fiellin DA, O'Connor PG, Chawarski M, Schottenfeld RS. Processes of Care During a Randomized Trial of Office‐based Treatment of Opioid Dependence in Primary Care. American Journal On Addictions 2004, 13: s67-s78. PMID: 15204676, DOI: 10.1080/10550490490440843.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFemaleFocus GroupsHumansMaleMedical AuditMethadoneMiddle AgedMulticenter Studies as TopicNarcoticsOffice VisitsOpioid-Related DisordersOutcome and Process Assessment, Health CarePrimary Health CareProcess Assessment, Health CareQuality Assurance, Health CareRandomized Controlled Trials as TopicReferral and ConsultationSubstance Abuse DetectionTreatment RefusalUnited StatesConceptsUrine toxicology resultsProcess of careOpioid dependenceChart auditToxicology resultsOpioid treatment programsOffice-based careOffice-based treatmentDependent patientsMethadone maintenancePrimary carePsychiatric servicesFocus groupsQuality careTreatment programCareTreatmentTrialsAuditMedicationsBuprenorphinePatientsMethadoneGroupEvaluation of processes
2002
New federal initiatives to enhance the medical treatment of opioid dependence.
Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Annals Of Internal Medicine 2002, 137: 688-92. PMID: 12379070, DOI: 10.7326/0003-4819-137-8-200210150-00014.Peer-Reviewed Original ResearchConceptsOpioid dependenceMedical treatmentOpioid agonist medicationsRole of internistsAgonist medicationsPharmacologic treatmentMaintenance treatmentNew medicationsMedical conditionsOffice settingSubstantial healthMedicationsPatientsTreatmentInternistsRecent federal initiativesFederal initiativesNew federal initiativesComplicationsCareIncreasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study
Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O’Connor P, Selwyn PA. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine 2002, 55: 235-246. PMID: 12144138, DOI: 10.1016/s0277-9536(01)00167-8.Peer-Reviewed Original ResearchConceptsActive drug usersDrug users' adherenceDrug usersDrug treatmentMedical carePrimary careIntervention feasibility studySocial support structuresHealth advocatesUser adherenceTreatment program staffPeer-driven interventionHIV diseaseHIV infectionPatient adherenceSix-month studyHIV treatmentPhysician referralClinical appointmentsHIV therapeuticsCarePositive behavioral changesAdherencePeer pressureTreatment
2001
Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement
Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement. JAMA Psychiatry 2001, 58: 755-761. PMID: 11483141, PMCID: PMC3651594, DOI: 10.1001/archpsyc.58.8.755.Peer-Reviewed Original ResearchConceptsDrug-free urine specimensNaltrexone treatmentFamily counseling sessionsContingency managementOpioid dependenceTreatment retentionUrine specimensBehavioral therapyOpioid-dependent individualsCounseling sessionsDrug use outcomesSubstance abuse outcomesNaltrexone complianceNaltrexone therapyOpioid useAvailable pharmacotherapiesMedication complianceSpecific pharmacotherapySignificant improvementTherapyUse outcomesAbuse outcomesPrincipal outcomePharmacotherapyTreatment
2000
Pharmacologic treatment of heroin-dependent patients.
O'Connor P, Fiellin D. Pharmacologic treatment of heroin-dependent patients. Annals Of Internal Medicine 2000, 133: 40-54. PMID: 10877739, DOI: 10.7326/0003-4819-133-1-200007040-00008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHeroin dependenceHeroin-dependent patientsDrug treatment settingsBehavioral health problemsOpioid withdrawalPharmacologic treatmentMethadone maintenanceHeroin usePhysician's officeTreatment approachesTreatment settingsHealth problemsPatientsRelapse preventionTreatmentPhysiciansAcetylmethadolBuprenorphineInternistsReferralDiagnosisAlternative sitesPreventionHIV post-exposure therapy for drug users in treatment
O'Connor P. HIV post-exposure therapy for drug users in treatment. Journal Of Substance Use And Addiction Treatment 2000, 18: 17-21. PMID: 10636602, DOI: 10.1016/s0740-5472(99)00015-x.Peer-Reviewed Original ResearchConceptsPost-exposure therapyMethadone maintenance programDrug usersOccupational exposurePrimary care providersCross-sectional evaluationHIV prevention messagesGroups of providersNonoccupational exposureProvider staffNeedle stickDrug treatmentCare providersFocus groupsPrevention messagesTreatment programProgram providersTreatment staffFurther studiesHIVFuture riskTherapyTreatmentCase vignettesExposure